Evonile Pharma Approves Rights Issue to Raise Up to ₹9,000 Million
Novartis India Ltd · Others (Uncategorized) · 09 Oct 2026, 12:40 am
Evonile Pharma Approves Rights Issue to Raise Up to ₹9,000 Million The Board of Directors of Evonile Pharma Limited (formerly Novartis India Limited) approved raising up to ₹9,000 million through a rights issue of partly paid-up equity shares with a face value of ₹5 each at its meeting on 8th Oct'26. The board constituted a Rights Issue Committee to finalize the issue terms, price, entitlement ratio, and record date. The fundraising remains subject to shareholder approval via postal ballot and statutory clearances. Additionally, the company launched its new corporate website under the name Evonile Pharma.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
